Advertisements



AstraZeneca's Lynparza shown to put brakes on ovarian cancer - Reuters

ReutersAstraZeneca's Lynparza shown to put brakes on ovarian cancerReutersMUNICH (Reuters) - An AstraZeneca drug that blocks a cancer cell's ability to repair its g.....»»

Category: topSource: googlenewsOct 22nd, 2018

AstraZeneca"s Lynparza approved as 1st line ovarian cancer maintenance treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 18th, 2019

Merck and AstraZeneca"s Lynparza granted positive EU opinion in ovarian cancer

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 29th, 2019

Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA

PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer. Shares of TESARO, Inc. TSRO and Clovis Oncology.....»»

Category: worldSource: nytNov 14th, 2018

AstraZeneca to present update on ph3 trial of LYNPARZA in early breast cancer

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 19th, 2021

AstraZeneca"s cancer drug sees early unblinding in key trial, Reuters reports

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 12th, 2020

The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak.....»»

Category: earningsSource: benzingaMar 12th, 2020

Merck-AstraZeneca"s Lynparza Snags FDA Nod For Pancreatic Cancer

In what co.....»»

Category: blogSource: benzingaDec 30th, 2019

AstraZeneca, Merck say Lynparza approved in U.S. in gBRCAm pancreatic cancer

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 30th, 2019

AstraZeneca says FDA advisors recommend Lynparza for gBRCAm pancreatic cancer

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 17th, 2019

AstraZeneca/Merck"s Lynparza Wins EU Nod for Breast Cancer

AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for tr.....»»

Category: worldSource: nytApr 10th, 2019

AstraZeneca reports EU approval for Lynparza for certain ovarian cancers

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 8th, 2018

AstraZeneca"s Two New Cancer Drugs Get Approval in Japan

AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication a.....»»

Category: worldSource: nytJul 3rd, 2018

Hitting cancer early: AstraZeneca"s bid to outmaneuver rivals

LONDON (Reuters) - AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit......»»

Category: topSource: reutersJul 6th, 2018

J&J ordered to pay $4.7 billion to women after claims its products gave them cancer

Mike Segar/Reuters Johnson & Johnson has been ordered to pay $4.69 billion to women who said its baby powder product gave them ovarian cancer, fo.....»»

Category: topSource: businessinsiderJul 13th, 2018

AstraZeneca"s (AZN) Lynparza Gets Another Orphan Drug Status

AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer. AstraZeneca plc AZN and .....»»

Category: dealsSource: nytOct 16th, 2018

AstraZeneca"s Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows

AstraZeneca's updated data from TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in advanced biliary tract cancer patients. Unveiling long-term survival benefits and significant overall survival improvement. read more.....»»

Category: blogSource: benzingaApr 16th, 2024

Sutro Biopharma ovarian cancer data "impressive," says Piper Sandler

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 20th, 2021

Aspira Women"s Health to reveal ovarian cancer risk assessment technology

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 13th, 2021

Aspira Women"s Health initiates clinical study for Ovarian Cancer risk detection

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 12th, 2021

European Union Announce Second Lawsuit Against AstraZeneca Over Delayed COVID-19 Vaccine Supply: Reuters

read more.....»»

Category: blogSource: benzingaMay 11th, 2021